Published by Coherent Market Insights
Posted on September 30, 2021
4 min readLast updated: February 1, 2026
The Zika Vaccines Market is projected to reach USD 22.1 billion by 2027, driven by the high incidence of Zika virus infections and ongoing R&D efforts.
Zika Vaccines Market (Forecast Period 2021-2028): The report provides a valuable source of insightful data for business strategists and competitive analysis of Zika Vaccines Market. The study covers important knowledge that makes the analysis document a handy resource for managers, analysts, business consultants and different key individuals get ready-to-access and self-analyzed study in conjunction with graphs and tables to assist perceive market trends, drivers and market challenges.It also highlights the restraints and opportunities expected to influence the market’s growth during the said period. The study provides a holistic perspective on the market’s growth throughout the above mentioned forecast period in terms of revenue(in US$ Mn) and Volume (Thousand Units), across different geographies.
To Access the Sample Report Click Here: https://www.coherentmarketinsights.com/insight/request-sample/413
Note: *The Sample only consist of Table of Content (ToC), Research Framework of the actual report, and Research Methodology adopted for it.
Major Players In This Market Are: Cerus Corporation, Biken Inc, GlaxoSmithKline plc, Bharat Biotech International Pvt. Ltd, GeneOne Life Science, Inovio Pharmaceuticals, Immunovaccine Inc., NewLink Genetics Corp. and Sanofi S.A.
The Zika vaccines market is expected to witness significant growth, due to high incidence of Zika virus infection. In November 2019, The European Centers for Disease Control confirmed the first three cases of Zika that started in southern France. Zika is spread mostly by the bite of an infected Aedes species mosquito. These mosquitoes bite during the day and night. Recently, there have been clusters of cases of meningitis, encephalitis, meningitis and other neurological conditions caused by the disease. There are also links to birth defects and neurological problems in some of the babies born to infected mothers. Such concerns are expected to aid in growth of the Zika vaccines market.
R&D of new products is expected to aid in growth of the Zika vaccines market. Currently, a licensed product, in the form of a live virus extract, is under clinical trials. A Zika vaccine is targeted at preventing the complications and symptoms of pregnancy-related Zoonotic infections caused by the strain of Aedes species. Since it is generally associated with an airborne infection, it was assumed that a vaccine would be needed to prevent infection during pregnancy. There have been no clinical trials testing the safety of this vaccine in pregnant women, however, since the product’s development stage involves both in vitro and in silico technologies.
North America Zika vaccines market is driven by R&D of new products. The Canadian Pest Management Regulatory Authority is currently evaluating four related Zika virus vaccines in development. The first is a type 2 injectable vaccine intended for women of childbearing age; the second is a vehicle injected in kittens that prevent the infection from occurring in kittens that are not immunized; the third is a whole virus product designed to be administered to pregnant mothers; and the fourth is an in vitro cell culture product aimed at preventing the infection in cell cultures. These vaccines are currently being evaluated in phase 1 clinical trials. No medication has been proven to stop or prevent the spread of the zika virus, but vaccines can reduce the risk to infants and mothers when infected.
The clinical trial procedures vary according to the type of product being tested. In the case of the in-vitro zika virus vaccine candidates, which are manufactured in the laboratories and then distributed by means of nasal trays into the nasal cavity, the primary test procedure involves exposing the vaccines to irritants and then monitoring the reaction of the mice for approximately two hours post-exposure. The product is expected to be able to protect mice from infection if at least one injection is successful.
Buy This Premium Report Of Zika Vaccines Market Report 2021 With Flat USD 2000 OFF @ https://www.coherentmarketinsights.com/promo/buynow/413
In this study, the years considered to estimate the market size of Zika Vaccines are as follows:
History Year: 2017-2020
Base Year: 2020
Estimated Year: 2021
Forecast Year 2021 to 2028
The next part also sheds light on the gap between supply and consumption. Apart from the mentioned information, growth rate of Zika Vaccines Market in 2028 is also explained. Additionally, type wise and application wise consumption tables and figures of Zika Vaccines Market are also given.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
The post Zika Vaccines Market Size Is Projected to Reach USD 22.1 billion at a CAGR of 5.1% By 2027 appeared first on Gatorledger.
The main topic is the projected growth of the Zika Vaccines Market to USD 22.1 billion by 2027.
Major players include Cerus Corporation, GlaxoSmithKline, and Sanofi S.A.
The market growth is driven by the high incidence of Zika virus infections and R&D of new products.
Explore more articles in the Research Reports category
